GlassScriptPhysician profile
Vidya S Rajpara
NPI 1962613943
$5,909.51
in general payments reported to CMS, 2019-2025
33 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $121 · 2021: $1,443 · 2022: $1,086 · 2023: $736 · 2024: $743 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,552.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,905.34 | 2019-2025 | |
| Revance Therapeutics, INC. | $468.60 | 2024-2025 | Daxi, Daxxify |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $352.63 | 2019-2023 | Arazlo, Jublia |
| Almirall LLC | $308.76 | 2019-2022 | |
| Allergan, INC. | $299.37 | 2019-2022 | |
| Amgen INC. | $264.47 | 2021-2024 | Otezla |
| Lnhc, INC | $259.55 | 2025 | Zelsuvmi |
| Genzyme Corporation | $225.83 | 2019-2022 | |
| Organon LLC | $190.51 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $179.40 | 2019-2024 | |
| Pfizer INC. | $169.02 | 2021-2025 | |
| Medtronic, INC. | $139.00 | 2025 | Interstim |
| Novartis Pharmaceuticals Corporation | $137.42 | 2019-2025 | |
| Janssen Biotech, INC. | $118.56 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $92.60 | 2021-2025 | Absorica Ld, Winlevi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $89.89 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $86.96 | 2019-2021 | |
| Ucb, INC. | $85.79 | 2020-2024 | Bimzelx, Cimzia |
| Leo Pharma INC. | $81.33 | 2019-2025 | Adbry |
| Mayne Pharma Commercial LLC | $69.46 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $52.72 | 2022-2023 | |
| Vyne Pharmaceuticals INC. | $44.01 | 2020-2021 | |
| Dermavant Sciences, INC. | $37.74 | 2023-2024 | Vtama |
| Kerecis Limited | $37.64 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Lilly USA, LLC | $37.26 | 2021-2024 | Taltz |
| Botanix Sb INC | $32.79 | 2025 | Sofdra |
| Boston Scientific Corporation | $30.42 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.33 | 2023 | Spevigo |
| Incyte Corporation | $23.54 | 2025 | Opzelura |
| Helsinn Therapeutics (U.S.), INC. | $18.69 | 2019 | |
| Merz North America, INC. | $17.26 | 2021 | |
| Blueprint Medicines Corporation | $15.53 | 2024 | Ayvakit |
| Biofrontera INC. | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vidya Rajpara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.